NCT00432107 - A Study to Assess APO866 for the Treatment of Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2009

Conditions

Melanoma

Interventions

DRUG

APO866

APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles

Trial Locations (6)

Department of Dermatology, Medical University Graz, Graz

Department of Dermatology, University Hospital of Zürich, Zurich

Department of Dermatology, Charité University Hospital Berlin, Berlin

Department of Dermatologie, Hotel Dieu, Nantes

University Clinic for Dermatology, Medical Faculty of Mannheim of the Heidelberg University, Mannheim

Department of Dermatology, Hopital Henri Modor, Créteil